Two cases of acquired hypothalamic obesity in adults showed significant weight loss with GLP-1 drug therapy, demonstrating efficacy in brain injury-induced obesity that resists conventional treatment.
Brain-damaged appetite, drugs still workEven when the brain's appetite center is damaged, GLP-1 drugs produced meaningful weight loss — working through alternative pathways
What the researchers found
Two adults with acquired hypothalamic obesity achieved significant weight loss with GLP-1 drug therapy, demonstrating non-hypothalamic weight loss mechanisms for treatment-resistant obesity.
Why it matters
Hypothalamic obesity is devastating and untreatable. Two successful cases suggest GLP-1 drugs could help.
How the study worked
Two-case experience of obesity medications including GLP-1 drugs in adults with acquired hypothalamic obesity.
What this study cannot tell us
Only two cases. Cannot generalize. Small signal.
How to read the evidence
Two case reports.
When this study was published
Published in 2025.
The bigger picture
GLP-1 drugs work through multiple brain and peripheral mechanisms. Even when the hypothalamus is damaged, other pathways enable weight loss.
Questions still open
- Should all hypothalamic obesity patients try GLP-1 drugs?
- Which non-hypothalamic mechanisms drive weight loss in these patients?
- Would a larger case series confirm this benefit?
Common questions
Can GLP-1 drugs help when brain damage causes obesity?
Why is hypothalamic obesity so hard to treat?
Read the original research
Obesity medications and acquired hypothalamic obesity in adults: A two-case experience.
Obesity pillars, 17, 100246
Citation
Lang, Henry; Dorand, Madisen F; Hassan, Mahnooor; Richards, Jesse R. (2026). Obesity medications and acquired hypothalamic obesity in adults: A two-case experience.. Obesity pillars, 17, 100246. https://doi.org/10.1016/j.obpill.2026.100246